查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999528

內視鏡逆行性胰造影（ERCP）市場：依手術類型、產品類型、應用及最終用戶分類－2026年至2032年全球市場預測

Endoscopic Retrograde Cholangiopancreatography Market by Procedure Type, Product, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，內視鏡逆行性造影(ERCP) 市值將達到 22.1 億美元，到 2026 年將成長至 23.9 億美元，到 2032 年將達到 38.7 億美元，年複合成長率為 8.28%。

主要市場統計數據
基準年 2025 22.1億美元
預計年份：2026年 23.9億美元
預測年份 2032 38.7億美元
複合年成長率 (%) 8.28%

對現代 ERCP 生態系統進行全面介紹，重點介紹臨床應用、設備分類以及診斷和治療實踐的交匯點。

內視鏡逆行性造影（ERCP）仍然是肝膽胰醫學的核心手術之一，是診斷影像和治療性介入之間的橋樑。近年來，該手術已從主要用於診斷的造影和造影發展成為以治療主導的模式，強調括約肌切開術、支架置入術和取石術等標靶干預。隨著臨床實踐向微創內視鏡解決方案轉變，臨床醫生和採購負責人需要清晰了解影響技術應用和治療結果的技術進步、最佳實踐和發展趨勢。

找出改變 ERCP 實踐的關鍵變化，例如影像技術的進步、單人膽道鏡檢查的日益普及以及相關設備的創新。

內視鏡逆行性胰膽管攝影術（ERCP）領域正經歷一場變革，主要得益於影像技術、單人膽道鏡技術和輔助器材創新技術的同步發展。先進的視訊處理器和最佳化的光源顯著提升了可視性，從而提高了病灶檢出率和手術精準度。同時，單人膽道鏡系統的日益成熟，拓展了直接視覺化能力，能夠支援靶向碎石和組織取樣。這些技術主導的變革也得益於輔助器械設計的改進，例如更靈活的導管導引線、改良的括約肌切開器以及旨在減少組織反應和輸送的支架平台。

評估美國關稅變更到 2025 年對 ERCP醫療設備供應鏈、籌資策略和臨床實踐准入的累積影響。

在美國，2025年實施的關稅政策正對醫療設備供應鏈施加累積壓力，需要謹慎的策略性因應。某些零件和成品進口關稅的提高，導致內視鏡系統、成像平台和高精度配件的到貨成本上升。因此，採購團隊必須在有限的資金預算和臨床應用需求之間取得平衡，這迫使他們不僅要考慮單價，還要考慮臨床療效和整體擁有成本。

基於詳細細分的洞察揭示了手術類型、產品類型、臨床應用和醫療保健環境如何共同決定 ERCP 的實施和採購。

深入的市場區隔闡明了手術決策、產品架構、臨床應用和醫療環境如何相互交織，共同塑造器材的使用和創新路徑。根據手術類型，市場被分類為診斷和治療兩大類。診斷類再細分為造影及造影，而治療類則進一步細分為括約肌切開術、支架置放術及體外震波碎石術。這些手術類型上的區分至關重要，因為診斷流程優先考慮影像的精確性和可操作性，而治療流程則需要耐用的配件、可靠的支架輸送系統以及針對體外震波碎石術和組織操作最佳化的工具。

影響美洲、歐洲、中東和非洲以及亞太地區 ERCP 採用和供應鏈策略的關鍵區域趨勢和實施模式。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的技術應用、臨床實踐模式和供應鏈結構的影響各不相同。在美洲，對整合式醫療保健系統和價值醫療的高度重視推動了對能夠展現手術效率和可衡量療效的醫療器材的需求。同時，領先的三級醫療中心繼續發揮關鍵作用，率先採用者先進的膽道鏡和體外碎石技術。各地區的支付方結構也影響採購時機以及為了最佳化現金流而選擇直接購買還是融資租賃的意願。

公司層面的趨勢重點關注內視鏡、成像平台、配件設計以及策略夥伴關係的創新，這些創新正在加速臨床部署。

某些製造商、臨床創新者和技術整合商正在推動ERCP工具及其相關生態系統的當前發展。領先的內視鏡和成像平台供應商已投資研發高解析度視訊處理器和最佳化光源，以提高診斷清晰度和手術成功率。同時，專業配件製造商正致力於開發更易於置入的支架系統、微創括約肌切開器和高效能碎石器械，以縮短手術時間並降低併發症風險。這些產品層面的創新通常會與強化培訓專案、服務交付和數據驅動的支援相結合，以促進其應用推廣。

為行業領導者提供實用建議，以協調產品設計、臨床證據和供應鏈韌性，從而加速部署並帶來可衡量的價值。

產業領導者應採取多管齊下的策略，將產品創新、臨床證據產生和供應鏈韌性結合，以保持競爭優勢並改善患者預後。首先，優先考慮模組化和互系統結構，這將使醫療機構能夠在不更換整個內視鏡平台的情況下升級成像和處理組件，從而降低採用先進可視化技術的資金門檻。投資舊有系統和向下相容的配件也有助於拓展目標市場並簡化採購決策。

採用穩健的混合調查方法，結合專家訪談、臨床文獻回顧和實際場景映射，來檢驗ERCP 的趨勢和影響。

本執行摘要的分析採用了一種結構化的研究方法，該方法結合了與關鍵相關人員的直接溝通以及包含臨床和監管二手資訊的全面研究。主要研究包括對執業內視鏡醫師、醫院採購經理、專科診所負責人和醫療設備原始設備製造商 (OEM) 的訪談，以了解當前的應用模式、未滿足的需求以及影響採購決策的因素。除了這些訪談之外，還透過納入操作觀察和臨床教育者的回饋，檢驗了關於訓練需求和工作流程整合的假設。

明確整合 ERCP 策略挑戰，強調技術、臨床證據和協作方法，以改善醫療保健並控制成本壓力。

總而言之，目前ERCP的特點是技術快速進步、診療模式轉向以治療為先的照護模式轉變，以及受區域政策和收費系統影響的採購趨勢不斷演變。影像技術的改進、單人操作膽道鏡的廣泛應用以及輔助設備的創新，正在擴大內視鏡介入治療膽道和胰臟疾病的有效性和適用範圍。同時，人們也越來越關注手術安全、操作者培訓以及支援永續實施的互系統結構，這些臨床和技術促進因素也隨之湧現。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 內視鏡逆行性造影（ERCP）市場依手術類型分類

  • 診斷
    • 造影
    • 造影
  • 治療
    • 括約肌切開術
    • 支架置入
    • 石材移除

第9章 內視鏡逆行性造影（ERCP）市場：依產品分類

  • 配件
  • 內視鏡系統
  • 影像系統
    • 光源
    • 影像處理設備

第10章 內視鏡逆行性造影（ERCP）市場：依應用領域分類

  • 膽道疾病
    • 膽結石
    • 洩漏
    • 收縮
  • 胰臟疾病
    • 胰臟炎
    • 瘤

第11章 內視鏡逆行性造影（ERCP）市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章 內視鏡逆行性造影（ERCP）市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 內視鏡逆行性造影（ERCP）市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 內視鏡逆行性造影（ERCP）市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國內視鏡逆行性胰造影（ERCP）市場

第16章：中國逆行性造影（ERCP）內視鏡市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ambu A/S
  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • CONMED Corporation
  • Cook Medical LLC
  • Fujifilm Holdings Corporation
  • HOYA Corporation
  • Huger Medical Instrument Co., Ltd.
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Medi-Globe GmbH
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Micro-Tech Endoscopy Co., Ltd.
  • Olympus Corporation
  • SonoScape Medical Corporation
  • STERIS plc
  • TeleMed Systems, Inc.
Product Code: MRR-5A2C6AA6657B

The Endoscopic Retrograde Cholangiopancreatography Market was valued at USD 2.21 billion in 2025 and is projected to grow to USD 2.39 billion in 2026, with a CAGR of 8.28%, reaching USD 3.87 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.21 billion
Estimated Year [2026] USD 2.39 billion
Forecast Year [2032] USD 3.87 billion
CAGR (%) 8.28%

Comprehensive introduction to the contemporary ERCP ecosystem highlighting clinical scope, device categories, and the intersection of diagnostic and therapeutic practice

Endoscopic retrograde cholangiopancreatography remains a cornerstone procedure at the interface of diagnostic imaging and therapeutic intervention within hepatobiliary and pancreatic care. Over recent years, the procedure has evolved from principally diagnostic cholangiography and pancreatography into a therapy-driven modality emphasizing targeted interventions such as sphincterotomy, stent placement, and stone extraction. As clinical practice pivots toward minimally invasive endoscopic solutions, practitioners and procurement professionals alike require a clear synthesis of technological advances, procedural best practices, and the shifting dynamics that influence adoption and outcomes.

This executive summary consolidates essential themes that define contemporary ERCP practice and the device ecosystem that supports it. By examining advances in endoscope systems, imaging adjuncts such as light sources and video processors, and the full complement of accessories, the analysis maps the trajectory of clinical innovation alongside practical considerations of safety, training, and supply chain resilience. Importantly, the content addresses both biliary system disorders including gallstones, leaks, and strictures, and pancreatic system disorders such as pancreatitis and tumors, reflecting the broad clinical footprint of ERCP.

Readers will find an integrated perspective that balances procedural detail with strategic foresight. The aim is to enable clinicians, health-system procurement leaders, and device innovators to make informed choices that align clinical efficacy with operational realities, regulatory constraints, and evolving payer expectations. Transitional commentary throughout this document highlights opportunities to reduce adverse events, improve patient throughput, and leverage technological differentiation to advance care quality.

Identifying the major transformative shifts altering ERCP practice including imaging enhancements, single-operator cholangioscopy adoption, and accessory innovation

The ERCP landscape is undergoing transformative shifts driven by parallel advances in imaging, single-operator cholangioscopy, and accessory innovation. Enhanced visualization provided by modern video processors and optimized light sources has improved lesion detection and procedural precision, while the maturation of single-operator cholangioscopy systems has expanded direct-visualization capabilities that support targeted lithotripsy and tissue acquisition. These technology-led changes are complemented by improvements in accessory design including more flexible guidewires, refined sphincterotomes, and stent platforms engineered for deliverability and reduced tissue reaction.

Concurrently, clinical practice has trended toward therapeutic-first approaches in many indications, with endoscopists increasingly favoring minimally invasive interventions over surgical alternatives when clinically appropriate. This clinical pivot is reinforced by growing evidence for procedural safety optimization, with prophylactic strategies against post-procedure pancreatitis such as rectal nonsteroidal anti-inflammatory drug use and selective pancreatic stenting becoming standard components of many care pathways. Training and simulation have also expanded, supporting operator proficiency in complex maneuvers and new device utilization, thereby accelerating safe adoption.

Supply chain diversification and the pursuit of interoperability across imaging and endoscope platforms represent additional systemic shifts. As hospitals and ambulatory centers seek to streamline inventories while ensuring clinical efficacy, there is greater emphasis on modular systems and accessories that deliver consistent performance across a range of clinical settings. Taken together, these shifts are reshaping how institutions prioritize capital investments, design clinical workflows, and partner with manufacturers to co-develop solutions that align with evolving standards of care.

Assessing the cumulative impact of tariff shifts in the United States through 2025 on ERCP device supply chains, procurement strategies, and clinical access

In the United States, tariff policies enacted through 2025 have exerted cumulative pressures on the medical device supply chain that warrant careful strategic response. Increased import duties on selected components and finished devices have elevated landed costs for endoscope systems, imaging platforms, and high-precision accessories. As a result, procurement teams must reconcile the clinical imperative of advanced technology adoption with constrained capital budgets, prompting prioritization exercises that emphasize clinical impact and total cost of ownership rather than unit price alone.

Manufacturers and distributors have responded with diversified sourcing strategies, relocating portions of manufacturing, assembly, or component production to mitigate exposure to tariff-sensitive supply lines. This re-shoring and near-shoring activity has introduced both opportunities and complexities: while proximity to end markets can shorten lead times and reduce exposure to cross-border duties, it may also necessitate new capital investments, regulatory approvals, and workforce training. Moreover, some suppliers have shifted product portfolios to emphasize domestically manufactured components or alternative materials that are less affected by tariff classifications, enabling continued market access while preserving margins.

Clinicians and health systems have adapted procurement behavior by increasing collaboration with vendors on pricing models, bundled purchasing, and service-level agreements that absorb parts of tariff-driven cost variability. In parallel, there has been greater interest in retrofit and modular upgrade strategies for existing endoscope and imaging platforms to extend usable lifecycles without full capital replacement. Ultimately, the cumulative tariff environment through 2025 has reinforced the imperative for cross-functional planning among clinical, supply chain, and finance stakeholders to preserve access to clinical innovations while managing cost volatility.

Deep segmentation-driven insights revealing how procedure type, product architecture, clinical application, and care setting jointly determine ERCP adoption and procurement

Insightful segmentation clarifies how procedural decision-making, product architecture, clinical indication, and care setting intersect to shape device utilization and innovation pathways. Based on Procedure Type, market is studied across Diagnostic and Therapeutic; the Diagnostic is further studied across Cholangiography and Pancreatography while the Therapeutic is further studied across Sphincterotomy, Stent Placement, and Stone Extraction. These procedural distinctions matter because diagnostic workflows prioritize imaging fidelity and maneuverability, whereas therapeutic workflows demand durable accessories, reliable stent delivery systems, and tools optimized for extraction and tissue manipulation.

Based on Product, market is studied across Accessories, Endoscope Systems, and Imaging Systems; the Imaging Systems is further studied across Light Sources and Video Processors. Product segmentation highlights the layered nature of procurements where core capital equipment investments in endoscope systems and imaging platforms are paired with high-turnover accessory portfolios that influence recurring spend and clinical throughput. Accessories often drive procedure-level performance metrics, and their compatibility with legacy systems is a common determinant of purchasing decisions.

Based on Application, market is studied across Biliary System Disorders and Pancreatic System Disorders; the Biliary System Disorders is further studied across Gallstones, Leaks, and Strictures while the Pancreatic System Disorders is further studied across Pancreatitis and Tumors. Application-based segmentation underscores the clinical drivers of device selection, as the management of gallstones or strictures may prioritize lithotripsy-capable platforms and stent technology, while tumor-related indications often require enhanced imaging, biopsy capability, and multidisciplinary coordination. Finally, based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics. End-user segmentation reflects variability in capital budgets, case complexity, and throughput expectations, with ambulatory centers focusing on efficiency and cost control, hospitals balancing high-acuity caseloads with teaching and research imperatives, and specialty clinics emphasizing niche expertise and longitudinal patient management.

Key regional dynamics and adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape ERCP deployment and supply chain strategies

Regional dynamics influence technology adoption, clinical practice patterns, and supply chain configurations in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidation among health systems and a strong emphasis on value-based care are driving demand for devices that demonstrate procedural efficiency and measurable outcomes, while centers of excellence in tertiary hospitals continue to serve as early adopters of advanced cholangioscopy and lithotripsy technologies. Regional payer structures also influence procurement timing and the appetite for bundled purchasing or capital leasing arrangements that optimize cash flow.

Within Europe, the Middle East & Africa, heterogeneity in regulatory regimes and healthcare funding models creates a mosaic of adoption rates. Some countries with centralized procurement favor standardized platforms that can be deployed broadly, whereas others prioritize innovation within leading academic centers. In several EMEA markets, efforts to expand minimally invasive care pathways are stimulating interest in training programs and partnerships that accelerate operator skill acquisition, thus creating a pipeline for broader device uptake.

Asia-Pacific presents a highly dynamic environment where rapid clinical capacity expansion and large patient volumes have spurred investment in both capital equipment and workforce development. High-volume centers in major metropolitan areas often pioneer new procedural workflows and leverage scale to negotiate favorable procurement terms. Simultaneously, regional manufacturing hubs and component suppliers have become important nodes in the global supply chain, affecting availability and pricing of accessories and replacement parts. Across all regions, cross-border collaboration, regulatory harmonization efforts, and clinical evidence generation continue to shape how devices are evaluated and adopted in practice.

Company-level dynamics highlighting innovation in endoscopes, imaging platforms, accessory design, and strategic partnerships that accelerate clinical adoption

A focused set of manufacturers, clinical innovators, and technology integrators are driving the current evolution of ERCP tools and supporting ecosystems. Leading endoscope and imaging platform providers have invested in higher-resolution video processors and optimized light sources to improve diagnostic clarity and procedural confidence. Concurrently, accessory specialists have concentrated on developing more deliverable stent systems, low-trauma sphincterotomes, and efficient stone extraction tools that reduce procedure time and complication risk. These product-level innovations are frequently paired with enhanced training programs, service offerings, and data-driven support to facilitate adoption.

Strategic partnerships between device firms and clinical centers have become more common, accelerating real-world evidence collection and enabling iterative product refinement. In addition, manufacturers are increasingly offering bundled service and maintenance programs that reduce total lifecycle costs and provide predictable budgeting for end users. Distribution partners and system integrators play a pivotal role in ensuring compatibility between endoscope systems and third-party imaging modules, and they often contribute to after-sales training and support which are critical for complex therapeutic procedures.

Finally, newer entrants and niche innovators focusing on cholangioscopy-guided lithotripsy, biodegradable stents, and single-use accessory concepts are reshaping competitive dynamics. Their presence encourages incumbents to improve product differentiation and to expand clinical studies that demonstrate tangible improvements in safety or efficiency. Collectively, these company-level trends underscore a market where clinical credibility, service excellence, and interoperability are central to commercial success.

Actionable recommendations for industry leaders to align product design, clinical evidence, and supply chain resilience to accelerate adoption and deliver measurable value

Industry leaders should adopt a multi-pronged strategy that aligns product innovation, clinical evidence generation, and supply chain resilience to sustain competitive advantage and improve patient outcomes. First, prioritizing modular and interoperable system architectures will allow institutions to upgrade imaging or processing components without replacing entire endoscope platforms, thereby reducing capital barriers to adopting advanced visualization. Investing in accessories that are backward-compatible with legacy systems can also expand addressable markets and ease procurement decisions.

Second, companies and health systems should co-invest in robust clinical evidence programs that measure not only immediate procedural outcomes but also longitudinal metrics such as reintervention rates, health-economic impact, and patient-reported outcomes. These data will be critical to justify adoption in value-conscious purchasing environments and to support payer engagement. Third, developing tariff-mitigation strategies such as diversified sourcing, near-shoring critical component production, and transparent pricing models will reduce exposure to policy-driven cost variability and improve supply predictability.

Fourth, expanding operator training and simulation offerings will both speed safe adoption of advanced techniques and reduce complication rates that can erode confidence in new technologies. Finally, adopting outcome-based contracting and bundled-service models can align incentives between manufacturers, providers, and payers, promoting broader access to innovations while sharing the financial risk of new technology deployment.

Robust mixed-methods research methodology combining expert interviews, clinical literature review, and practical scenario mapping to validate ERCP trends and implications

The analysis underpinning this executive summary synthesizes a structured research approach that blends primary stakeholder engagement with comprehensive secondary review of clinical and regulatory sources. Primary research included interviews with practicing endoscopists, hospital procurement leaders, specialty clinic administrators, and device OEM representatives to capture current adoption patterns, unmet needs, and procurement decision drivers. These conversations were augmented by procedural observations and input from clinical educators to validate assumptions about training requirements and workflow integration.

Secondary research incorporated peer-reviewed clinical literature, regulatory filings, device labeling, and publicly available procedural guidelines to ensure technical accuracy and alignment with contemporary clinical practice. Where appropriate, registries and procedural outcome datasets were canvassed to corroborate trends in complication mitigation strategies and device utilization. Attention was given to recent advances in imaging technology, single-operator cholangioscopy modalities, and accessory-driven innovations to reflect the most relevant developments influencing clinical decision-making.

Analytical methods included thematic synthesis of qualitative inputs and triangulation across sources to identify consistent patterns and strategic implications. The methodology also entailed scenario mapping to assess the operational impacts of supply chain disruptions and tariff-related cost shifts, enabling practical recommendations that are responsive to both clinical and commercial realities.

Conclusive synthesis of ERCP strategic imperatives emphasizing technology, clinical evidence, and collaborative approaches to advance care and manage cost pressures

In sum, the ERCP landscape is characterized by rapid technological refinement, procedural shifts toward therapeutic-first care, and evolving procurement dynamics shaped by regional policy and tariff influences. Improved imaging, the rise of single-operator cholangioscopy, and accessory innovation are collectively enhancing the efficacy and scope of endoscopic interventions for biliary and pancreatic disorders. These clinical and technological drivers are occurring alongside heightened attention to procedural safety, operator training, and interoperable system architectures that support sustainable adoption.

Going forward, stakeholders who successfully integrate clinical evidence, flexible product design, and supply chain strategies will be best positioned to deliver improved patient outcomes while managing cost and access pressures. Collaboration among device manufacturers, clinical centers, and payers will be essential to translate incremental innovations into measurable clinical and economic value. By focusing on interoperability, lifecycle cost management, and outcome-oriented contracting, organizations can navigate current headwinds and seize opportunities to expand the role of ERCP in minimally invasive hepatobiliary and pancreatic care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endoscopic Retrograde Cholangiopancreatography Market, by Procedure Type

  • 8.1. Diagnostic
    • 8.1.1. Cholangiography
    • 8.1.2. Pancreatography
  • 8.2. Therapeutic
    • 8.2.1. Sphincterotomy
    • 8.2.2. Stent Placement
    • 8.2.3. Stone Extraction

9. Endoscopic Retrograde Cholangiopancreatography Market, by Product

  • 9.1. Accessories
  • 9.2. Endoscope Systems
  • 9.3. Imaging Systems
    • 9.3.1. Light Sources
    • 9.3.2. Video Processors

10. Endoscopic Retrograde Cholangiopancreatography Market, by Application

  • 10.1. Biliary System Disorders
    • 10.1.1. Gallstones
    • 10.1.2. Leaks
    • 10.1.3. Strictures
  • 10.2. Pancreatic System Disorders
    • 10.2.1. Pancreatitis
    • 10.2.2. Tumors

11. Endoscopic Retrograde Cholangiopancreatography Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Endoscopic Retrograde Cholangiopancreatography Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endoscopic Retrograde Cholangiopancreatography Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endoscopic Retrograde Cholangiopancreatography Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Endoscopic Retrograde Cholangiopancreatography Market

16. China Endoscopic Retrograde Cholangiopancreatography Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Ambu A/S
  • 17.6. B. Braun Melsungen AG
  • 17.7. Boston Scientific Corporation
  • 17.8. CONMED Corporation
  • 17.9. Cook Medical LLC
  • 17.10. Fujifilm Holdings Corporation
  • 17.11. HOYA Corporation
  • 17.12. Huger Medical Instrument Co., Ltd.
  • 17.13. Johnson & Johnson
  • 17.14. KARL STORZ SE & Co. KG
  • 17.15. Medi-Globe GmbH
  • 17.16. Medtronic plc
  • 17.17. Merit Medical Systems, Inc.
  • 17.18. Micro-Tech Endoscopy Co., Ltd.
  • 17.19. Olympus Corporation
  • 17.20. SonoScape Medical Corporation
  • 17.21. STERIS plc
  • 17.22. TeleMed Systems, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY CHOLANGIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPHINCTEROTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STENT PLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STONE EXTRACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY ENDOSCOPE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LIGHT SOURCES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY VIDEO PROCESSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GALLSTONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY LEAKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY STRICTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)